
    
      The study population will be composed of 3 subgroups of participants as follows:

        -  Participants rolling over from the pivotal Phase 3 pediatric efficacy studies (Studies
           TV48125-CNS-30082 and TV48125-CNS-30083)

        -  Participants rolling over from the Phase 1 pediatric pharmacokinetic study (Study
           TV48125-CNS-10141)

        -  Participants rolling over from the pivotal Phase 3 pediatric efficacy studies (Studies
           TV48125-CNS-30082 and TV48125-CNS-30083) for safety follow-up and antidrug antibody
           (ADA) evaluation only
    
  